GTC
RNAM

Ghost Tree Capital’s Avidity Biosciences RNAM Stock Holding History

Ghost Tree Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-65,000
Closed -$415K – 68
2023
Q3 		$415K Hold
65,000
– – 0.14% 67
2023
Q2 		$721K Sell
65,000
-60,000
-48% -$753K 0.24% 49
2023
Q1 		$1.92M Buy
125,000
+25,000
+25% +$550K 0.57% 42
2022
Q4 		$2.22M Buy
+100,000
New +$1.49M 0.95% 28

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ghost Tree Capital's RNAM Position: Q4 2023 in Review

Ghost Tree Capital sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 65,000 shares — an estimated $415K sold.

Ghost Tree Capital first reported a position in RNAM in Q4 2022 and held it in 4 quarters. The position peaked at $2.22M in Q4 2022. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Ghost Tree Capital reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 65,000 Avidity Biosciences shares in Q4 2023, an estimated $415K.
  • Ghost Tree Capital first reported a position in Avidity Biosciences in Q4 2022 and held it in 4 quarters.
  • Ghost Tree Capital's Avidity Biosciences position peaked at $2.22M in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.